Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A

5(71.4%)

Phase 2

1(14.3%)

Phase 1

1(14.3%)

7Total

N/A(5)

Phase 2(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07552818Not ApplicableNot Yet Recruiting

Neuroprotection in Acute Cerebral Ischemia II

Role: lead

NCT06753136Not ApplicableRecruiting

Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype

Role: collaborator

NCT04883411Not ApplicableRecruiting

CEM-Plate and CEM-Cage First-In-Human Use Efficacy Study

Role: collaborator

NCT05803681Not ApplicableCompleted

CCEF in the Treatment of Acute VFFs: Randomized Controlled Trial

Role: collaborator

NCT03225781Not ApplicableTerminated

Electrochemoterapy With Bleomycin for the Treatment of Unresectable Pancreatic Cancer

Role: collaborator

NCT02883023Phase 2Unknown

Electrosclerotherapy for Capillary Malformations

Role: collaborator

NCT02709811Phase 1Terminated

Safety and Feasibility of Electrochemotherapy in Unresectable Colorectal Adenocarninoma Liver Metastases

Role: lead

All 7 trials loaded